|
Name |
11-Eicosenoic acid, methyl ester
|
Molecular Formula | C21H40O2 | |
IUPAC Name* |
methyl (E)-icos-11-enoate
|
|
SMILES |
CCCCCCCC/C=C/CCCCCCCCCC(=O)OC
|
|
InChI |
InChI=1S/C21H40O2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21(22)23-2/h10-11H,3-9,12-20H2,1-2H3/b11-10+
|
|
InChIKey |
RBKMRGOHCLRTLZ-ZHACJKMWSA-N
|
|
Synonyms |
11-Eicosenoic acid, methyl ester; 69119-90-0; Methyl 11-eicosenoate; 3946-08-5; 11-eicosenoic acid methyl ester; METHYL TRANS-11-EICOSENOATE; Methyl cis-icos-11-enoate; Methyl (11E)-11-icosenoate; SCHEMBL2189519; 11-Icosenoic acid methyl ester; Methyl (11E)-11-eicosenoate; DTXSID701346307; Methyl (11E)-11-icosenoate #; EINECS 219-226-8; ZINC85530227; trans-11-Eicosenoic acid methyl ester; J-015264; Q63399176
|
|
CAS | 2390-09-2 | |
PubChem CID | 5319603 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 324.5 | ALogp: | 8.7 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 18 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 23 | QED Weighted: | 0.165 |
Caco-2 Permeability: | -4.885 | MDCK Permeability: | 0.00002020 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.886 |
30% Bioavailability (F30%): | 0.998 |
Blood-Brain-Barrier Penetration (BBB): | 0.148 | Plasma Protein Binding (PPB): | 99.14% |
Volume Distribution (VD): | 4.269 | Fu: | 0.90% |
CYP1A2-inhibitor: | 0.282 | CYP1A2-substrate: | 0.191 |
CYP2C19-inhibitor: | 0.361 | CYP2C19-substrate: | 0.062 |
CYP2C9-inhibitor: | 0.165 | CYP2C9-substrate: | 0.97 |
CYP2D6-inhibitor: | 0.513 | CYP2D6-substrate: | 0.104 |
CYP3A4-inhibitor: | 0.47 | CYP3A4-substrate: | 0.047 |
Clearance (CL): | 3.457 | Half-life (T1/2): | 0.361 |
hERG Blockers: | 0.333 | Human Hepatotoxicity (H-HT): | 0.038 |
Drug-inuced Liver Injury (DILI): | 0.135 | AMES Toxicity: | 0.002 |
Rat Oral Acute Toxicity: | 0.011 | Maximum Recommended Daily Dose: | 0.04 |
Skin Sensitization: | 0.966 | Carcinogencity: | 0.041 |
Eye Corrosion: | 0.919 | Eye Irritation: | 0.936 |
Respiratory Toxicity: | 0.832 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002275 | 1.000 | D0O1PH | 0.692 | ||||
ENC001678 | 0.917 | D07ILQ | 0.575 | ||||
ENC001657 | 0.909 | D0O1TC | 0.483 | ||||
ENC001680 | 0.909 | D0Z5SM | 0.481 | ||||
ENC001682 | 0.909 | D00FGR | 0.454 | ||||
ENC001540 | 0.909 | D00AOJ | 0.446 | ||||
ENC001688 | 0.909 | D0OR6A | 0.441 | ||||
ENC000572 | 0.909 | D05ATI | 0.430 | ||||
ENC001687 | 0.881 | D0UE9X | 0.414 | ||||
ENC001435 | 0.818 | D00MLW | 0.389 |